AI-Enhanced TCR-pMHC Affinity Modeling Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides an AI-Enhanced TCR-pMHC Affinity Modeling Service to address key challenges in TCR-T development, including the identification of high-affinity TCR candidates, accurate prediction of TCR–pMHC binding strength, and the reduction of time-consuming experimental screening. This service enables rapid prioritization of optimal TCR candidates through advanced computational modeling, structural simulations, and machine-learning-guided affinity analysis. By integrating structural immunology with predictive analytics, Creative Biolabs delivers data-driven insights that accelerate TCR candidate optimization and support efficient development of next-generation TCR-T immunotherapies.

Introduction

TCR recognition of peptide-MHC complexes is the central mechanism underlying T-cell immune responses and TCR-T therapies. Studies integrating structural biology, molecular simulation, and machine learning demonstrate that computational modeling can effectively predict TCR-pMHC binding affinity and interaction stability. Recent research indicates that structural interface features, sequence motifs, and energetic calculations can be integrated to estimate binding free energy and identify promising TCR candidates. AI-assisted modeling, therefore, provides a powerful strategy to accelerate TCR discovery and reduce experimental screening workloads.

Service

Creative Biolabs offers a computational platform for TCR-T candidate discovery and optimization via predictive modeling of TCR-peptide-MHC interactions. This service allows research teams to rapidly evaluate candidate receptors prior to experimental validation, converting the complexity of T cell receptor recognition into actionable data. By delivering quantitative insights, it moves beyond trial-and-error approaches and helps prioritize candidates with the highest potential for clinical success.

Our project support encompasses high-accuracy TCR-pMHC binding energy prediction, structure-guided candidate ranking, mutational optimization of CDR and interface residues, cross-reactivity risk assessment, and data-driven candidate selection to enhance affinity, specificity, safety, and rational prioritization of TCR-T candidates.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Creative Biolabs integrates multiple computational approaches to evaluate TCR-pMHC interactions and predict binding strength. The service incorporates several mainstream analysis strategies commonly used in immunotherapy research.

Structural Modeling of TCR-pMHC Complexes
Predictive modeling reconstructs the three-dimensional complex structure of TCR, peptide antigen, and MHC molecules. Structural models enable analysis of interaction geometry and interface compatibility.
AI-Driven Binding Affinity Prediction	Molecular Interaction Energy Analysis
Machine-learning algorithms analyze sequence and structural features to estimate relative binding affinity and binding energy trends across candidate TCR sequences.	Energy calculations assess hydrogen bonding, electrostatic interactions, and hydrophobic contacts that contribute to TCR-pMHC stability.
Computational Mutagenesis Analysis	Interface Feature Profiling
Residue scanning methods evaluate potential mutations within complementarity-determining regions to identify variants with improved predicted affinity.	Detailed interface mapping identifies key contact residues, binding hotspots, and structural constraints relevant to receptor engineering.

Our Workflow

To initiate the project, clients typically provide TCR sequences, specifically the CDR3 beta region or full alpha\beta chains, and Target Epitope/MHC Allele details.

Workflow of AI-Enhanced TCR-pMHC Affinity Modeling Service. (Creative Biolabs Original)

Final Deliverables: Clients receive a detailed Therapeutic Candidate Evaluation Report, including ranked affinity scores, Cross-Reactivity Risk Profiles, and high-resolution Binding Interaction Maps visualizing key hydrogen bonds and hydrophobic contacts.

Core Benefits

Customized TRAP Framework: Specialized contrastive learning that enhances generalizability for unseen epitopes not present in public databases.
High-Dimensional Feature Mapping: Integration of both sequence and 3D structural environment data (local atomic symmetry functions).
Advanced Cross-Reactivity Screening: Capability to diagnose potential side effects by evaluating TCR binding across similar epitopes or MHC-restricted conformations.
Unified Negative Sampling: A robust sampling strategy that prevents learning shortcuts, ensuring predictions are based on biology rather than dataset distribution.
Aromatic/Hydrophobic Interaction Analysis: Specialized modeling of aromatic rings, which are critical drivers of strong TCR-pMHC stability.

FAQs

Q: How does your AI model handle epitopes not present in the training data?

A: We utilize a contrastive learning framework that aligns TCR and pMHC features in a shared representation space, allowing the model to generalize based on biophysical patterns rather than just memorizing sequences.

Q: Can your service distinguish between Class I and Class II MHC alleles?

A: Yes, we support modeling for various alleles. While much of the recent work focuses on Class I, our feature space is designed to integrate the structural parameters of both MHC classes.

Q: What is the advantage of including structural data over sequence-only models?

A: Structural modeling captures conformational changes near the epitope that sequence data misses. This is critical for distinguishing subtle variations in binding strength and predicting true cross-reactivity.

Q: Is this service suitable for large-scale TCR repertoire screening?

A: Absolutely. Our computational pipeline is designed for high-throughput analysis, allowing you to screen thousands of sequences and narrow them down to a handful of validated hits.

Partner with Us

Creative Biolabs stands as your trusted and innovative partner in pioneering the next generation of highly specific and effective TCR-T immunotherapies. Our state-of-the-art AI-Enhanced TCR-pMHC Affinity Modeling Service effectively bridges the critical gap between high-throughput omics sequencing and successful, safe clinical translation, empowering researchers to accelerate rational candidate design, optimize therapeutic performance, and drive breakthroughs in adaptive cell therapy. Contact Our Expert Team today for more detailed information, customized solutions, and in-depth discussions about your unique project goals and requirements.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.